Decramer, Marc <br/><br/>
Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials.  [electronic resource] 

 -  The Lancet. Respiratory medicine  Jun 2014 
 - 472-86 p.  digital 
<br/><br/> Publication Type: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>2213-2619 
<br/><br/><label>Standard No.: </label>10.1016/S2213-2600(14)70065-7  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Administration, Inhalation<br/>Aged<br/>Benzyl Alcohols--administration & dosage<br/>Bronchodilator Agents--administration & dosage<br/>Chlorobenzenes--administration & dosage<br/>Dose-Response Relationship, Drug<br/>Double-Blind Method<br/>Drug Combinations<br/>Female<br/>Follow-Up Studies<br/>Forced Expiratory Volume--drug effects<br/>Humans<br/>Male<br/>Middle Aged<br/>Pulmonary Disease, Chronic Obstructive--drug therapy<br/>Quinuclidines--administration & dosage<br/>Scopolamine Derivatives--administration & dosage<br/>Time Factors<br/>Tiotropium Bromide<br/>Treatment Outcome